Antigen News and Research

RSS

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.

31 Aug 2017

Researcher uses gold nanoparticles and lasers to target bladder cancer

A University of Colorado Cancer Center study takes a new approach to killing cancer: Why not fry it into oblivion with vibrating gold nanoparticles? "But what about the frickin' lasers?" you may ask. Don't worry. There are lasers. And bioluminescence too.

31 Aug 2017

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

The U.S. Food and Drug Administration (FDA) has issued a press release making the first even gene therapy available for treatment of children with a form of acute lymphoblastic leukemia (ALL).

30 Aug 2017

$Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL$

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

30 Aug 2017

New biomedical tool using nanoparticles could improve therapies for many diseases

A new biomedical tool using nanoparticles that deliver transient gene changes to targeted cells could make therapies for a variety of diseases -; including cancer, diabetes and HIV -; faster and cheaper to develop, and more customizable.

30 Aug 2017

FDA approves first cell-based gene therapy for use in the United States

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

30 Aug 2017

Researchers develop new approach to efficiently produce versatile antibody therapies

A group of researchers has developed an approach to efficiently produce antibodies that can bind to two different target molecules simultaneously, a long-desired innovation in the field of cancer immunotherapy.

29 Aug 2017

GW study to explore the body's natural defenses against HIV

A research team at the George Washington University School of Medicine and Health Sciences will study the body's natural defenses against HIV and look for ways to eliminate the infectious HIV reservoirs in the white blood cells of people taking antiretroviral therapy.

28 Aug 2017

Simultaneous treatment with anti-PD1 and anti-OX40 cancer therapies may have detrimental effect

Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

28 Aug 2017

NIH grant for CWRU professors could enable new directions for cancer immunotherapies

Nicole Steinmetz, PhD, Associate Professor of Biomedical Engineering, Radiology, member of the Case Comprehensive Cancer Center and the Center for RNA Science and Therapeutics in the Division of General Medical Sciences at Case Western Reserve University School of Medicine and the holder of the George J. Picha Designated Professor in Biomaterials, has received a major grant from the National Institutes of Health to help understand how a virus-like particle from plants stimulates potent anti-tumor responses.

26 Aug 2017

Pan-European initiative receives €3.7 million funding to train next generation of brain tumor researchers

A pan-European initiative led by the University of Plymouth designed to train the next generation of brain tumor researchers, has received funding of almost €3.7 million from the European Commission's Horizon 2020 - Research and Innovation Framework Program.

26 Aug 2017

Discovery sheds new light on biological phenomenon in autoimmune disease

A newly-unveiled discovery, which has been four years in the making, has the potential to change the way we look at autoimmune diseases and understand how and why immune cells begin to attack different tissues in the body.

24 Aug 2017

Rare transition metal can simplify design and preparation of antibody therapies

Rice University scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells. Adding a little extra metal is the key.

24 Aug 2017

FDA approves Besponsa – Pfizer’s new drug for rare form of acute lymphoblastic leukemia

The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.

17 Aug 2017

$FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL$

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

17 Aug 2017

Study reveals strong prognostic indicators of survival in resected pancreatic cancer

A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.

10 Aug 2017

Researchers hope to harness immune cells for better treatment of allergies, infections

By learning how a recently discovered immune cell works in the body, researchers hope to one day harness the cells to better treat allergies and infections, according to new Cornell University research.

4 Aug 2017

Protein that protects fetus during pregnancy could help treat atopic dermatitis

A protein which protects the fetus during pregnancy, HLA-G1, shows high potential for treating atopic dermatitis and other related diseases.

4 Aug 2017

TUM scientists provide new insights into development of T cells

When T cells encounter an antigen, they proliferate and produce various types of daughter cells. A team at the Technical University of Munich has now refuted the prevailing hypothesis that this immune response is largely predetermined by the individual structure of the T cell receptor.

2 Aug 2017

Antigen News and Research

Pfizer receives FDA approval for new therapy to treat adults and children with AML

UChicago Medicine working with Novartis to offer breakthrough gene therapy for pediatric ALL patients

Researcher uses gold nanoparticles and lasers to target bladder cancer

FDA makes the first gene therapy Kymriah available for treatment of pediatric ALL

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

New biomedical tool using nanoparticles could improve therapies for many diseases

FDA approves first cell-based gene therapy for use in the United States

Researchers develop new approach to efficiently produce versatile antibody therapies

GW study to explore the body's natural defenses against HIV

Simultaneous treatment with anti-PD1 and anti-OX40 cancer therapies may have detrimental effect

NIH grant for CWRU professors could enable new directions for cancer immunotherapies

Pan-European initiative receives €3.7 million funding to train next generation of brain tumor researchers

Discovery sheds new light on biological phenomenon in autoimmune disease

Rare transition metal can simplify design and preparation of antibody therapies

FDA approves Besponsa – Pfizer’s new drug for rare form of acute lymphoblastic leukemia

FDA approval provides new, targeted treatment option for adults with relapsed or refractory B-cell ALL

Study reveals strong prognostic indicators of survival in resected pancreatic cancer

Researchers hope to harness immune cells for better treatment of allergies, infections

Protein that protects fetus during pregnancy could help treat atopic dermatitis

TUM scientists provide new insights into development of T cells

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News